- Home
- TAVI vs AARD Comparison
TAVI vs AARD Comparison
Compare TAVI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAVI
- AARD
- Stock Information
- Founded
- TAVI 2024
- AARD 2017
- Country
- TAVI United States
- AARD United States
- Employees
- TAVI N/A
- AARD N/A
- Industry
- TAVI
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- TAVI
- AARD Health Care
- Exchange
- TAVI Nasdaq
- AARD Nasdaq
- Market Cap
- TAVI 164.0M
- AARD 186.3M
- IPO Year
- TAVI 2024
- AARD 2025
- Fundamental
- Price
- TAVI $10.35
- AARD $17.05
- Analyst Decision
- TAVI
- AARD Strong Buy
- Analyst Count
- TAVI 0
- AARD 7
- Target Price
- TAVI N/A
- AARD $31.43
- AVG Volume (30 Days)
- TAVI 20.0K
- AARD 237.1K
- Earning Date
- TAVI 01-01-0001
- AARD 11-14-2025
- Dividend Yield
- TAVI N/A
- AARD N/A
- EPS Growth
- TAVI N/A
- AARD N/A
- EPS
- TAVI 5.42
- AARD N/A
- Revenue
- TAVI N/A
- AARD N/A
- Revenue This Year
- TAVI N/A
- AARD N/A
- Revenue Next Year
- TAVI N/A
- AARD N/A
- P/E Ratio
- TAVI $1.91
- AARD N/A
- Revenue Growth
- TAVI N/A
- AARD N/A
- 52 Week Low
- TAVI $9.89
- AARD $4.88
- 52 Week High
- TAVI $10.72
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- TAVI N/A
- AARD 81.66
- Support Level
- TAVI N/A
- AARD $10.75
- Resistance Level
- TAVI N/A
- AARD $14.32
- Average True Range (ATR)
- TAVI 0.00
- AARD 1.13
- MACD
- TAVI 0.00
- AARD 0.63
- Stochastic Oscillator
- TAVI 0.00
- AARD 91.19
About TAVI Tavia Acquisition Corp. Ordinary Shares
Tavia Acquisition Corp is a blank check company.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.